Voyager Therapeutics
VYGR
138 hedge funds and large institutions have $430M invested in Voyager Therapeutics in 2019 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 47 increasing their positions, 40 reducing their positions, and 18 closing their positions.
6,285% more call options, than puts
Call options by funds: $830K | Put options by funds: $13K
44% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 18
18% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 40
5% more funds holding
Funds holding: 131 → 138 (+7)
0.17% more ownership
Funds ownership: 83.06% → 83.23% (+0.17%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
19% less capital invested
Capital invested by funds: $528M → $430M (-$98M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$7.67M |
| 2 |
Millennium Management
New York
|
+$7.16M |
| 3 |
Bank of New York Mellon
New York
|
+$6.65M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.71M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$4.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$21.2M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$8.61M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$4.56M |
| 4 |
ClearBridge Investments
New York
|
-$3.29M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.38M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LWCFA
151
Loring Wolcott & Coolidge Fiduciary Advisors
Boston,
Massachusetts
| – | -$36K | -2,100 | Closed |
|
|
QT
152
Quantamental Technologies
White Plains,
New York
| – | -$25K | -1,430 | Closed |
|
|
FWM
153
Focused Wealth Management
Newburgh,
New York
| – | -$17K | -1,000 | Closed |
|
154
Lazard Asset Management
New York
| – | -$15K | -913 | Closed |
|
155
Fifth Third Bancorp
Cincinnati,
Ohio
| – | -$14K | -800 | Closed |
|
|
TRCT
156
Tower Research Capital (TRC)
New York
| – | -$9K | -539 | Closed |
|
VYGR Hedge Fund Activity: Q4 2019 in Review
138 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q4 2019, worth a combined $430M — down 19% from $528M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new VYGR positions and 18 closed out — a net gain of 8 holders — while 47 added to existing stakes and 40 trimmed.
The largest buyer was Armistice Capital, adding an estimated $7.67M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $21.2M sold.
- 138 institutional investors held Voyager Therapeutics (VYGR) as of Q4 2019, up from 131 in Q3 2019.
- Funds reported $430M of Voyager Therapeutics stock for Q4 2019, down 19% quarter-over-quarter.
- 26 funds opened new Voyager Therapeutics positions in Q4 2019 and 18 closed out, a net change of +8 holders.
- The largest Voyager Therapeutics buyer in Q4 2019 was Armistice Capital, an estimated $7.67M added.
- The largest Voyager Therapeutics seller in Q4 2019 was PFM Health Sciences, an estimated $21.2M sold.
Based on aggregated 13F filings for Q4 2019.